Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $59,939,832 | $42,286,047 | $35,015,114 | $30,258,513 |
| - Cash | $1,490,249 | $1,113,685 | $1,019,654 | $966,428 |
| + Debt | $2,773,309 | $2,739,734 | $2,722,252 | $2,743,419 |
| Enterprise Value | $61,222,892 | $43,912,096 | $36,717,712 | $32,035,504 |
| Revenue | $1,249,026 | $773,689 | $594,189 | $593,166 |
| % Growth | 61.4% | 30.2% | 0.2% | – |
| Gross Profit | $1,051,795 | $630,736 | $523,148 | $490,349 |
| % Margin | 84.2% | 81.5% | 88% | 82.7% |
| EBITDA | $297,170 | $18,832 | $11,455 | -$140,911 |
| % Margin | 23.8% | 2.4% | 1.9% | -23.8% |
| Net Income | $251,084 | -$66,277 | -$57,479 | -$83,763 |
| % Margin | 20.1% | -8.6% | -9.7% | -14.1% |
| EPS Diluted | 1.84 | -0.51 | -0.44 | -0.65 |
| % Growth | 460.8% | -15.9% | 32.3% | – |
| Operating Cash Flow | $325,109 | $153,730 | -$118,314 | -$94,662 |
| Capital Expenditures | -$12,142 | -$14,293 | -$8,970 | -$9,094 |
| Free Cash Flow | $312,967 | $139,437 | -$127,284 | -$103,756 |